Results 131 to 140 of about 22,830 (226)

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer. [PDF]

Med Chem Res
Lee S, Hu L.
europepmc   +1 more source

Lorlatinib in ROS1-positive NSCLC [PDF]

Nature Reviews Clinical Oncology, 2019
openaire   +2 more sources

Case Report: Tyrosine kinase inhibitors in ROS1-rearranged and granulocyte colony-stimulating factor-producing lung squamous cell carcinoma. [PDF]

Front Oncol
Li R, Zhang S, Liu Z, Wu X.
europepmc   +1 more source

From phenotypic associations to clinical triage: promise and pitfalls of fusion-prediction models in non-small cell lung cancer. [PDF]

J Thorac Dis
Zeng G, He J, Zhong N.
europepmc   +1 more source

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study. [PDF]

MedComm (2020)
Zou Z, Zheng X, Tian P, Liu Z, Hu J, Fang Y, Xia Y, Ye F, Lv T, Li L, Zhong D, Zhou J, Chu Q, Shi M, Han C, Cao B, Huang D, Guo H, Lin G.   +18 more
europepmc   +1 more source

Development of clinical-radiological prediction models to prioritize <i>ALK</i>, <i>ROS1</i>, and <i>RET</i> fusion testing in major driver alteration-negative non-small cell lung cancer. [PDF]

J Thorac Dis
Wang Y, Xie Y, Yao X, Ke K, Ma P, Wang F, Liu Q, Xie X, Liu M, Lin X, Zhou C, Xie Z.   +11 more
europepmc   +1 more source

Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions. [PDF]

Int J Mol Sci
Delgado Leon F, de Armas SA, Molina M, Morales EG, Fernandez-Gomez M, Raez LE.   +5 more
europepmc   +1 more source

Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing. [PDF]

Med Sci (Basel)
Goel H, Majhi RK, Meena JP, Chopra A, Bakhshi S, Singh L, Seth R, Kar B, Tanwar P, Gupta AK.   +9 more
europepmc   +1 more source

Amplicon-based DNA and RNA unified NGS for enhanced fusion variant detection in suboptimal real-world NSCLC FFPE specimens. [PDF]

Transl Oncol
Feng Q, Wang Y, Huang M, Yang X, Lian S, Wang P, Qiao D, Zhang B, Zhang D, Gao N, Ma J, Gu Y, Xiong L, Lin D.   +13 more
europepmc   +1 more source

Correction: ROS1-1 [PDF]

Journal of Clinical Pathology, 2018
openaire   +2 more sources